Stege, H. M.
Bradfisch, F.
Fleischer, M. I.
Mohr, P.
Ugurel, S.
Terheyden, P.
Thiem, A.
Kiecker, F.
Leiter, U.
Becker, J. C.
Grabbe, S.
Loquai, C.
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Accepted: 25 August 2020
First Online: 4 September 2020
Compliance with Ethical Standards
:
: Becker JC: speaker honoraria from Amgen, Merck Serono, Sanofi, and Pfizer, advisory board honoraria from 4SC, Amgen, CureVac, eTheRNA, Lytix, Merck Serono, Novartis, ReProTher, Rigontec, and Sanofi as well as research funding from Alcedis, Amgen, Bristol-Myers Squibb, IQVIA, and Merck Serono; he also received travel support from 4SC and Incyte. Ugurel S: research support from Bristol Myers Squibb and Merck Serono; speakers and advisory board honoraria from Bristol Myers Squibb, Merck Sharp and Dohme, Merck Serono, Novartis and Roche, and travel support from Bristol Myers Squibb, Merck Sharp and Dohme. Terheyden P: speaker’s honoraria from BMS, Novartis, MSD, Pierre-Fabre, CureVac and Roche, consultant’s honoraria from BMS, Novartis, Pierre-Fabre, Merck Serono, Sanofi und Roche and travel support from BMS, Pierre-Fabre and Roche. Kiecker F: AdBoards/travel support/Speakers fee from Amgen, Novartis, BMS, MSD, Roche, Sanofi. Grabbe S: honoraria for advisory boards, oral presentations and travel expenses from Roche, Novartis, MSD, and BMS. Loquai C: received honoraria for advisory boards and oral presentations from Amgen, MSD, Roche, BMS, Novartis, Leo, Pierre Fabre; consultant for Roche-Posay, Roche, BMS and Biontech; travel expenses from Roche, Amgen, BMS, MSD and Novartis. Stege HM, Bradfisch F, Mohr P, Thiem A, Leiter U, Fleischer MI, and Schultheis M declare no conflict of interest.
: The multicenter collection of patient data was approved by the Ethics Committee of Rheinland-Pfalz (2019-14436) and was conducted in accordance with the principles of the Helsinki Declaration in its current version.
: Not applicable.